Last update 20 Mar 2025

Glimepiride/Vildagliptin/Metformin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
G/V/M
Target
DPP-4 x PRKAB1 x SUR1
Action
inhibitors, activators
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Laboratorios Silanes SA de CVLaboratorios Silanes SA de CV
Active Organization
Laboratorios Silanes SA de CVLaboratorios Silanes SA de CV
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC4H12ClN5
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N
CAS Registry1115-70-4
View All Structures (3)

Related

1
Clinical Trials associated with Glimepiride/Vildagliptin/Metformin Hydrochloride
NCT04841096
/ RecruitingPhase 3
Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure
100 Clinical Results associated with Glimepiride/Vildagliptin/Metformin Hydrochloride
Login to view more data
100 Translational Medicine associated with Glimepiride/Vildagliptin/Metformin Hydrochloride
Login to view more data
100 Patents (Medical) associated with Glimepiride/Vildagliptin/Metformin Hydrochloride
Login to view more data
100 Deals associated with Glimepiride/Vildagliptin/Metformin Hydrochloride
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
Mexico
Laboratorios Silanes SA de CVLaboratorios Silanes SA de CV
21 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ADA2024
Not Applicable
Diabetes Mellitus, Type 2
-
kcxmxmrdkr(tkmhmesstx) = Three mild hypoglycemic events were reported with the starting dose aedednlbvy (tlncqdjbbu )
-
14 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free